This is especially important in pancreatic cancer which usually demonstrates NF-κB activation, and is consistent with downstream signaling activation from Kras mutations which are present in the majority of pancreatic cancers [22, 23]. The gene discussed is KRAS; the disease is pancreatic neoplasm.